DACLATASVIR



Natdac


Indication:


Natdac (Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Natdac(Daclatasvir) should never be used without sofosbuvir. Natdac(Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name: Natdac

Active Ingeridents:Daclatasvir

Company Name: Natco

Package: 28 Tablets

Strength : 60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. Natdac(Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.


Dosage and Administration:


Take Natdac(Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking Natdac(Daclatasvir) without first talking with your healthcare provider.
  • Take Natdac(Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of Natdac(Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of Natdac(Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of Natdac(Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much Natdac(Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of Natdac(Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:


Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Precaution:


Before taking Natdac(Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Store:


Natdac(Daclatasvir) room temperature away from moisture and heat.


WARNING:


Natdac is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.






















Daclahep



Indication:


Daclahep(Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Daclahep(Daclatasvir) should never be used without sofosbuvir. Daclahep(Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name: Daclahep

Active Ingeridents: Daclatasvir

Company Name: Hetero

Package: 28 Tablets

Strength : 60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. Daclahep(Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.


Dosage and Administration:


Take Daclahep(Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking Daclahep(Daclatasvir) without first talking with your healthcare provider.
  • Take Daclahep(Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of Daclahep(Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of Daclahep(Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of Daclahep(Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much Daclahep(Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of Daclahep(Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:


Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Precaution:


Before taking Daclahep(Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.


Store:


Daclahep(Daclatasvir) room temperature away from moisture and heat.


WARNING:


Daclahep is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

















MyDacla



Indication:


MyDacla (Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. MyDacla (Daclatasvir) should never be used without sofosbuvir. MyDacla (Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name: MyDacla

Active Ingeridents: Daclatasvir

Company Name:Mylan

Package: 28 Tablets

Strength : 60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. MyDacla (Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.


Dosage and Administration:


Take MyDacla (Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking MyDacla (Daclatasvir) without first talking with your healthcare provider.
  • Take MyDacla (Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of (Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of MyDacla (Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of MyDacla (Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much (Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of MyDacla (Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:


Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Precaution:


Before taking MyDacla (Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Store:


MyDacla (Daclatasvir) room temperature away from moisture and heat.


WARNING:


MyDacla is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.



















Dacihep



Indication:


Dacihep(Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Dacihep(Daclatasvir) should never be used without sofosbuvir. Dacihep(Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name:Dacihep

Active Ingeridents: Daclatasvir

Company Name: Zydus Heptiza

Package: 28 Tablets

Strength : 60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. Dacihep(Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.


Dosage and Administration:


Take Dacihep(Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking Dacihep(Daclatasvir) without first talking with your healthcare provider.
  • Take Dacihep(Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of Dacihep(Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of Dacihep(Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of Dacihep(Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much Dacihep(Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of Dacihep(Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:


Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Precaution:


Before taking Dacihep(Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Store:


Dacihep(Daclatasvir) room temperature away from moisture and heat.


WARNING:


Dacihep is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
















Hepcfix



Indication:


Hepcfix(Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Hepcfix(Daclatasvir) should never be used without sofosbuvir. Hepcfix(Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name:Hepcfix

Active Ingeridents: Daclatasvir

Company Name: Dr.Reddy’s

Package: 28 Tablets

Strength : 60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. Hepcfix(Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.


Dosage and Administration:


Take Hepcfix(Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking Hepcfix(Daclatasvir) without first talking with your healthcare provider.
  • Take Hepcfix(Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of Hepcfix(Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of Hepcfix(Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of Hepcfix(Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much Hepcfix(Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of Hepcfix(Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:

Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Precaution:

Before taking Hepcfix(Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Store:


Hepcfix(Daclatasvir) room temperature away from moisture and heat.


WARNING:


Hepcfix is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

















DaclaCure



Indication:


DaclaCure(Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. DaclaCure(Daclatasvir) should never be used without sofosbuvir. DaclaCure(Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name:DaclaCure

Active Ingeridents: Daclatasvir

Company Name: Emcure

Package: 28 Tablets

Strength : 60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. DaclaCure(Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.



Dosage and Administration:


Take DaclaCure(Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking DaclaCure(Daclatasvir) without first talking with your healthcare provider.
  • Take DaclaCure(Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of DaclaCure(Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of DaclaCure(Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of DaclaCure(Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much DaclaCure(Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of DaclaCure(Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:


Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.


Precaution:


Before taking DaclaCure(Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.


Store:


DaclaCure(Daclatasvir) room temperature away from moisture and heat.


WARNING:


DaclaCure is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

















Hepcdac



Indication:


Hepcdac(Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Hepcdac(Daclatasvir) should never be used without sofosbuvir. Hepcdac(Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name: Hepcdac

Active Ingeridents: Daclatasvir

Company Name: Cipla

Package:28 Tablets

Strength : 60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. Hepcdac(Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.


Dosage and Administration:


Take Hepcdac(Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking Hepcdac(Daclatasvir) without first talking with your healthcare provider.
  • Take Hepcdac(Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of Hepcdac(Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of Hepcdac(Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of Hepcdac(Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much Hepcdac(Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of Hepcdac(Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:


Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Precaution:


Before taking Hepcdac(Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Store:


Hepcdac(Daclatasvir) room temperature away from moisture and heat.


WARNING:


Hepcdac is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

















Dalsiclear



Indication:


Dalsiclear(Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Dalsiclear(Daclatasvir) should never be used without sofosbuvir. Dalsiclear(Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name: Dalsiclear

Active Ingeridents: Daclatasvir

Company Name: Abbott India

Package: 28 Tablets

Strength : 60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. Dalsiclear(Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.


Dosage and Administration:


Take Dalsiclear(Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking Dalsiclear(Daclatasvir) without first talking with your healthcare provider.
  • Take Dalsiclear(Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of Dalsiclear(Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of Dalsiclear(Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of Dalsiclear(Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much Dalsiclear(Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of Dalsiclear(Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:


Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.


Precaution:


Before taking Dalsiclear(Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.


Store:


Dalsiclear(Daclatasvir) room temperature away from moisture and heat.


WARNING:


Dalsiclear is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.













Daclafab



Indication:


Daclafab(Daclatasvir) is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Daclafab(Daclatasvir) should never be used without sofosbuvir. Daclafab(Daclatasvir) and sofosbuvir may also be used with another antiviral medication (ribavirin). These medications together reduce the amount ofhepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.



Brand name: Daclafab

Active Ingeridents:Daclatasvir

Company Name: Ranbaxy

Package:28 Tablets

Strength :60 mg

Mechanism of action:


The dimeric symmetry of these compounds suggests that they act on a dimer of NS5A, which is also consistent with the presence of dimers in crystals of NS5A domain 1 from genotype 1b. Genotype 1a HCV is less potently affected by these compounds and resistance mutations have a greater effect than in the 1b genotypes. We have obtained crystals of domain 1 of the important 1a NS5A homologue and intriguingly, our X-ray crystal structure reveals two new dimeric forms of this domain. Furthermore, the high solvent content (75%) makes it ideal for ligand-soaking. Daclafab(Daclatasvir) (DCV) shows twofold symmetry suggesting NS5A dimers may be of physiological importance and serve as potential binding sites for DCV. These dimers also allow for new conformations of a NS5A expansive network which could explain its operation on the membranous web. Additionally, sulfates bound in the crystal structure may provide evidence for the previously proposed RNA binding groove, or explain regulation of NS5A domain 2 and 3 function and phosphorylation.


Dosage and Administration:


Take Daclafab(Daclatasvir) exactly as your healthcare provider tells you to.

  • Do not change your dose unless your healthcare provider tells you to.
  • Do not stop taking Daclafab(Daclatasvir) without first talking with your healthcare provider.
  • Take Daclafab(Daclatasvir) 1 time each day with or without food.
  • If you miss a dose of Daclafab(Daclatasvir), take the missed dose as soon as you remember the same day. Take the next dose at your regular time.
  • If you miss a dose of Daclafab(Daclatasvir) and remember the next day, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses of Daclafab(Daclatasvir) at the same time to make up for the missed dose.
  • If you take too much Daclafab(Daclatasvir), call your healthcare provider or go to the nearest hospital emergency room right away
  • The recommended usage of Daclafab(Daclatasvir) to treat chronic hepatitis C virus is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks.
  • Dose modification: Reduce dosage to 30 mg once daily with strong CYP3A4 inhibitors and increase dosage to 90 mg once daily with moderate CYP3A4 inducers.

Side effects:


Tiredness, headache, nausea, or diarrhea may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.


Precaution:


Before taking Daclafab(Daclatasvir), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.


Store:


Daclafab(Daclatasvir) room temperature away from moisture and heat.


WARNING:


Daclafab is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.